Angiogenesis Inhibitors and Stimulators: Therapeutic Strategies

Report Highlights

• The market for angiogenesis regulating agents is just emerging in 2001, with an estimated value of $100 million. It is expected to grow at an AAGR (average annual growth rate) of 88.8% to reach $2.4 billion by 2006. By 2006, angiogenesis inhibiting products are projected to represent a market approaching $1.8 billion.
• The biggest market for angiogenesis stimulating products will be for treatment of coronary artery disease and peripheral vascular disease. Drugs for these indications are expected to begin entering the market in 2004 with the introduction of GenVec's BioByPass. This is a gene therapy-based drug for the treatment of coronary artery disease and peripheral vascular disease.

INTRODUCTION

STUDY GOAL AND OBJECTIVES

This study provides a comprehensive analysis of emerging angiogenesis regulating technologies and the impact they will have on the treatment of disease. The report focuses primarily on angiogenesis inhibitors in development for cancer treatment and angiogenesis stimulators in development for the treatment of coronary artery disease and peripheral artery disease. However, information also is provided on other diseases for which angiogenesis regulation may be applicable, including autoimmune diseases, dermatological disorders, ocular diseases and wound healing. Forecasts for the overall angiogenesis regulation market are provided. Forecasts and trends are gleaned from industry sources as well as from considered assessment of this innovative technology.

REASONS FOR DOING THE STUDY

The regulation of angiogenesis, the development of blood vessels, is an area of much activity and promise. The blocking of angiogenesis is a quickly advancing strategy in the treatment of cancer, inflammatory and dermatological diseases and eye disorders. By blocking the formation of blood vessels in tumors, tumor growth is limited to pinhead-size lesions and metastasis is prevented. The stimulation of angiogenesis is under investigation as a way of replacing blocked blood vessels in the heart and peripheral arteries. Angiogenesis stimulation also is under study for enhancing wound repair.

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

This report explains the angiogenesis process and the technologies involved in its regulation. It offers information needed to understand the impact of angiogenesis-regulating products on disease treatment, as well as how these agents will fit into clinical protocols. It is an invaluable tool for planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investor consultants and anyone interested in angiogenesis regulation, its products, its industry participants and its future.

SCOPE AND FORMAT

This report primarily focuses on products in development to treat cancer and cardiovascular diseases, with discussions of selected products directed at other diseases.

The competitive environment is examined with a special focus on how new products and technologies will likely be used in the treatment of cancer and cardiovascular diseases, i.e., will these products be used as adjuncts to, or replacement therapy for currently available products and procedures. Profiles of companies in the late stages of development of angiogenesis-regulating products are provided.

Market figures are based on revenues at the manufacturers' level and are projected at 2001 dollar value, i.e., inflation is not computed into the projection figures. Trends are assessed based on projected product sales and must necessarily be estimates, since the timing of introduction and cost of these agents is not certain. Also included in this report are forecasts through 2006, including supporting analyses for projections.

METHODOLOGY

Information for preparing this study was derived from data supplied by product managers, marketing strategists, research executives and others at leading companies involved in the development of angiogenesis regulating agents. Data was accessed from government agencies and regulatory bodies that monitor and/or regulate pharmaceutical products. Searches of secondary material such as company annual reports and 10-Ks, journal articles, prospectus assessments, government resources and data from health care institutions also were conducted.

INFORMATION SOURCES

Information for this report was obtained from companies, organizations and institutions involved in the development of angiogenesis regulating agents, industry analysts, health care personnel, The Angiogenesis Foundation, the National Cancer Institute, the American Cancer Society, the American Heart Association, the Centers for Disease Control and Prevention and other government agencies, as well as from literature searches, annual reports, 10-Ks and product literature.